[1] Schatten H. Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies. ADV EXP MED BIOL 2018;1095:1-14.
[2] Lee DJ, Mallin K, Graves AJ, Chang SS, Penson DF, Resnick MJ, et al. Recent Changes in Prostate Cancer Screening Practices and Epidemiology. J Urol 2017;198:1230-40.
[3] Eeles R, Goh C, Castro E, Bancroft E, Guy M, Al OA, et al. The genetic epidemiology of prostate cancer and its clinical implications. NAT REV UROL 2014;11:18-31.
[4] Fenner A. Prostate cancer: ERSPC calculator recalibrated for China. NAT REV UROL 2017;14:66.
[5] Reulen RC, de Vogel S, Zhong W, Zhong Z, Xie LP, Hu Z, et al. Physical activity and risk of prostate and bladder cancer in China: The South and East China case-control study on prostate and bladder cancer. PLOS ONE 2017;12:e178613.
[6] Pezaro C, Woo HH, Davis ID. Prostate cancer: measuring PSA. INTERN MED J 2014;44:433-40.
[7] Duffy MJ. Biomarkers for prostate cancer: prostate-specific antigen and beyond. CLIN CHEM LAB MED 2019.
[8] Shore N. Management of early-stage prostate cancer. AM J MANAG CARE 2014;20:S260-72.
[9] Qu M, Ren SC, Sun YH. Current early diagnostic biomarkers of prostate cancer. ASIAN J ANDROL 2014;16:549-54.
[10] Bryant RJ, Lilja H. Emerging PSA-based tests to improve screening. Urol Clin North Am 2014;41:267-76.
[11] Rosenberg EE, Gerashchenko GV, Hryshchenko NV, Mevs LV, Nekrasov KA, Lytvynenko RA, et al. Expression of cancer-associated genes in prostate tumors. Exp Oncol 2017;39:131-7.
[12] Flores IE, Sierra-Fonseca JA, Davalos O, Saenz LA, Castellanos MM, Zavala JK, et al. Stress alters the expression of cancer-related genes in the prostate. BMC CANCER 2017;17:621.
[13] Filella X, Foj L. miRNAs as novel biomarkers in the management of prostate cancer. CLIN CHEM LAB MED 2017;55:715-36.
[14] Luu HN, Lin HY, Sorensen KD, Ogunwobi OO, Kumar N, Chornokur G, et al. miRNAs associated with prostate cancer risk and progression. BMC UROL 2017;17:18.
[15] Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions. BRIEF BIOINFORM 2014;15:1-19.
[16] Tafrihi M, Hasheminasab E. MiRNAs: Biology, Biogenesis, their Web-based Tools, and Databases. Microrna 2019;8:4-27.
[17] Rivera-Barahona A, Perez B, Richard E, Desviat LR. Role of miRNAs in human disease and inborn errors of metabolism. J INHERIT METAB DIS 2017;40:471-80.
[18] Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. NAT REV DRUG DISCOV 2017;16:203-22.
[19] Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol 2014;15:429.
[20] Li M, Huo X, Davuljigari CB, Dai Q, Xu X. MicroRNAs and their role in environmental chemical carcinogenesis. Environ Geochem Health 2019;41:225-47.
[21] Armand-Labit V, Pradines A. Circulating cell-free microRNAs as clinical cancer biomarkers. Biomol Concepts 2017;8:61-81.
[22] Kalinina EV, Ivanova-Radkevich VI, Chernov NN. Role of MicroRNAs in the Regulation of Redox-Dependent Processes. Biochemistry (Mosc) 2019;84:1233-46.
[23] Tian S, Guo X, Yu C, Sun C, Jiang J. miR-138-5p suppresses autophagy in pancreatic cancer by targeting SIRT1. Oncotarget 2017;8:11071-82.
[24] Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, et al. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget 2016;7:45370-84.
[25] Yang Z, Jiang S, Cheng Y, Li T, Hu W, Ma Z, et al. FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles. THER ADV MED ONCOL 2017;9:797-816.
[26] Han B, Bhowmick N, Qu Y, Chung S, Giuliano AE, Cui X. FOXC1: an emerging marker and therapeutic target for cancer. ONCOGENE 2017;36:3957-63.
[27] Ni WJ, Leng XM. miRNA-Dependent Activation of mRNA Translation. Microrna 2016;5:83-6.
[28] Stavast CJ, Erkeland SJ. The Non-Canonical Aspects of MicroRNAs: Many Roads to Gene Regulation. CELLS-BASEL 2019;8.
[29] Mork S, Pletscher-Frankild S, Palleja CA, Gorodkin J, Jensen LJ. Protein-driven inference of miRNA-disease associations. BIOINFORMATICS 2014;30:392-7.